Financial reports
ARS
2023 FY
Annual report to shareholders
18 Mar 24
10-K
2023 FY
Annual report
20 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
5 May 23
ARS
2022 FY
Annual report to shareholders
21 Mar 23
10-K
2022 FY
Annual report
17 Feb 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
Current reports
8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
3 Apr 24
8-K
Other Events
26 Feb 24
8-K
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
20 Feb 24
8-K
AbbVie Completes Acquisition of ImmunoGen
12 Feb 24
8-K
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
2 Feb 24
8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
5 Jan 24
8-K
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
6 Dec 23
8-K
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
30 Nov 23
8-K
AbbVie Reports Third-Quarter 2023 Financial Results
27 Oct 23
8-K
Departure of Directors or Certain Officers
12 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
26 Feb 24
FWP
Free writing prospectus
22 Feb 24
S-8
Registration of securities for employees
22 Feb 24
424B5
Prospectus supplement for primary offering
21 Feb 24
25-NSE
Exchange delisting
15 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jun 23
S-8
Registration of securities for employees
4 Nov 22
S-3ASR
Automatic shelf registration
22 Feb 22
S-8
Registration of securities for employees
12 May 21
25-NSE
Exchange delisting
4 May 21
Proxies
PX14A6G
Letter to shareholders
26 Mar 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
PRE 14A
Preliminary proxy
4 Mar 24
PX14A6G
Letter to shareholders
4 May 23
PX14A6G
Letter to shareholders
20 Apr 23
PX14A6G
Letter to shareholders
11 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Mar 23
PX14A6G
Letter to shareholders
28 Mar 23
PX14A6G
Letter to shareholders
27 Mar 23
Other
SD
Conflict minerals disclosure
31 May 23
UPLOAD
Letter from SEC
20 Oct 22
CORRESP
Correspondence with SEC
4 Oct 22
UPLOAD
Letter from SEC
20 Sep 22
SD
Conflict minerals disclosure
31 May 22
SD
Conflict minerals disclosure
1 Jun 21
UPLOAD
Letter from SEC
4 May 21
CORRESP
Correspondence with SEC
19 Mar 21
UPLOAD
Letter from SEC
16 Mar 21
CORRESP
Correspondence with SEC
15 Jan 21
Ownership
4
Susan E Quaggin
2 Apr 24
4
Robert J Alpern
2 Apr 24
4
EDWARD J RAPP
2 Apr 24
4
Nicholas Donoghoe
22 Mar 24
144/A
Notice of proposed sale of securities (amended)
21 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Jeffrey Ryan Stewart
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
TIMOTHY J. RICHMOND
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24